Join Conscio Group and leading industry experts on June 5, 2025, at 2:00 PM CET (expected duration up to 2 hours) for an exclusive webinar exploring the shifting balance between analytical similarity and clinical data in biosimilar development.
With regulatory expectations evolving, the importance of high-quality CMC and PK data has never been greater. Robust analytical evidence may reduce or even eliminate the need for large Phase 3 efficacy studies – but how do you convincingly demonstrate biosimilarity?
👉Register here to secure your spot. Participation is free!
Program highlights:
- The Future of Biosimilars: Leveraging Extensive Analytical Similarity for Regulatory Success
- Regulatory Strategies for Biosimilars: Past and Future.
- Patient Safety: Building Trustworthy Clinical Data for Biologics Approval
Speakers:
- Tharaka Rama Velisetty – CMC Sr Manager, IQVIA
- Parvinder Punia – Co-Founder, Pharmexon
- Jiří Juchelka, MD, MBA – Principal investigator, Conscio Group
Moderator: Stephan Holl, CEO, Conscio Group
Take this opportunity to gain expert insights, ask questions live, and get ahead of the curve in your biosimilar development strategy.
Missed our June 5th biosimilar webinar? The full recording is now available here: From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval | Recording
